Company’s 36-month beta value is 2.89.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SXTP is 1.37M, and currently, short sellers hold a 1.31% ratio of that floaft. The average trading volume of SXTP on June 20, 2025 was 1.60M shares.
SXTP) stock’s latest price update
The stock price of 60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) has dropped by -7.87 compared to previous close of 2.16. Despite this, the company has seen a fall of -12.72% in its stock price over the last five trading days. globenewswire.com reported 2025-06-04 that New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the introduction of a new 8-count bottle format for ARAKODA® (tafenoquine). The 8-count bottle format may be suitable for use with patients who are making shorter trips to areas of the world where malaria is endemic.
SXTP’s Market Performance
60 Degrees Pharmaceuticals Inc (SXTP) has experienced a -12.72% fall in stock performance for the past week, with a -16.03% drop in the past month, and a 0.51% rise in the past quarter. The volatility ratio for the week is 3.82%, and the volatility levels for the past 30 days are at 7.48% for SXTP.. The simple moving average for the past 20 days is -19.73% for SXTP’s stock, with a -51.06% simple moving average for the past 200 days.
SXTP Trading at -22.96% from the 50-Day Moving Average
After a stumble in the market that brought SXTP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.47% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SXTP starting from XU CHERYL, who purchase 5,000 shares at the price of $2.88 back on Jun 03 ’25. After this action, XU CHERYL now owns 15,816 shares of 60 Degrees Pharmaceuticals Inc, valued at $14,410 using the latest closing price.
XU CHERYL, the Director of 60 Degrees Pharmaceuticals Inc, purchase 6,000 shares at $1.56 during a trade that took place back on Dec 13 ’24, which means that XU CHERYL is holding 52,078 shares at $9,375 based on the most recent closing price.
Stock Fundamentals for SXTP
Current profitability levels for the company are sitting at:
- -15.71 for the present operating margin
- 0.4 for the gross margin
The net margin for 60 Degrees Pharmaceuticals Inc stands at -15.65. The total capital return value is set at -2.47. Equity return is now at value -181.43, with -142.93 for asset returns.
Currently, EBITDA for the company is -7.88 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -0.82. The receivables turnover for the company is 1.34for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.13.
Conclusion
In a nutshell, 60 Degrees Pharmaceuticals Inc (SXTP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
